United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - alprazolam (unii: yu55mq3izy) (alprazolam - unii:yu55mq3izy) - alprazolam 0.25 mg - xanax is indicated for the: xanax is contraindicated in patients: there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to psychiatric medications, including xanax, during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for psychiatric medications at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/research/pregnancyregistry/. neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal withdrawal [see warnings and precautions (5.8) and clinical considerations)] . available data from published observational studies of pregnant women exposed to benzodiazepines do not report a clear association with benzodiazepines and major birth defects (see data ). the background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adve

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - alprazolam (unii: yu55mq3izy) (alprazolam - unii:yu55mq3izy) - alprazolam 0.5 mg - xanax xr is indicated for the treatment of panic disorder with or without agoraphobia, in adults. xanax xr is contraindicated in patients: there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to psychiatric medications, including xanax xr, during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for psychiatric medications at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/pregnancyregistry/. neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal withdrawal [see warnings and precautions (5.8), and clinical considerations)] . available data from published observational studies of pregnant women exposed to benzodiazepines do not report a clear association with benzodiazepines and major birth defects (see data ). the background risk of major birth defects and miscarriage for the indicated population is unknown. all pre

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - triazolam (unii: 1hm943223r) (triazolam - unii:1hm943223r) - triazolam 0.25 mg - halcion is indicated for the short-term treatment of insomnia (generally 7 to 10 days) in adults. halcion is contraindicated in: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to psychiatric medications, including halcion, during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for psychiatric medications at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/pregnancyregistry/ risk summary neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal withdrawal [see warnings and precautions (5.10) and ]. available data from published observational studies of pregnant women exposed to benzodiazepines do not report a clear association with benzodiazepines and major birth defects (see ) . the background risk of major birth defects and miscarriage for the indicated population is unknown. all pr

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - alprostadil (unii: f5td010360) (alprostadil - unii:f5td010360) - prostin vr pediatric sterile solution is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of fallot, interruption of the aortic arch, coarctation of the aorta, or transposition of the great vessels with or without other defects. in infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment po2 values; that is, patients with low po2 values respond best, and patients with po2 values of 40 torr or more usually have little response. prostin vr pediatric should be administered only by trained personnel in facilities that provide pediatric intensive care. none.

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - arginine hydrochloride (unii: f7lth1e20y) (arginine - unii:94zla3w45f) - arginine hydrochloride 10 g in 100 ml - r-gene® 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for hgh can be of diagnostic usefulness. it can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature. if the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for hgh, a test with r-gene® 10 is advisable to confirm the negative response. this can be done after a waiting period of one day. as patients may not respond to r-gene® 10 (arginine hydrochloride injection, usp) during the first test, the unresponsive patient should be tested again to confirm the negative result. a second test can be performed after a waiting period of one day. some patients who respond to r-gene® 10 do not respond to insulin and vice versa. the rate of false positive responses for r-gene® 10 is approximately 32%, and the rate of false negatives is approximately 27%. the administration of r-gene® 10 is contraindicated in persons having known hypersensitivity to any ingredient in this product.

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - crisaborole (unii: q2r47hgr7p) (crisaborole - unii:q2r47hgr7p) -

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - bacitracin a (unii: dda3rrx0p7) (bacitracin a - unii:dda3rrx0p7) - in accordance with the statements in the "warning box" the use of intramuscular bacitracin is limited to the treatment of infants with pneumonia and empyema caused by staphylococci shown to be susceptible to the drug. to reduce the development of drug-resistant bacteria and maintain the effectiveness of bacitracin and other antibacterial drugs, bacitracin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. this drug is contraindicated in those individuals with a history of previous hypersensitivity or toxic reaction to it.

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - carboprost tromethamine (unii: u4526f86fj) (carboprost - unii:7b5032xt6o) - carboprost 250 ug in 1 ml - hemabate sterile solution is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: - failure of expulsion of the fetus during the course of treatment by another method; - premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; - requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; - inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. hemabate is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - clindamycin phosphate (unii: eh6d7113i8) (clindamycin - unii:3u02el437c) - clindamycin 10 mg in 1 ml - cleocin t topical solution, cleocin t topical gel and cleocin t topical lotion are indicated in the treatment of acne vulgaris. in view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate (see contraindications, warnings and adverse reactions). cleocin t topical solution, cleocin t topical gel and cleocin t topical lotion are contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin, a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis.

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - methylprednisolone sodium succinate (unii: lec9gky20k) (methylprednisolone - unii:x4w7zr7023) - when oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of solu-medrol sterile powder is indicated as follows: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. to tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (diamond-blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. for the palliative management of leukemias and lymphomas. acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. to induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). for the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. solu-medrol sterile powder is contraindicated: intramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura. additional contraindication for the use of solu-medrol sterile powder preserved with benzyl alcohol: formulations preserved with benzyl alcohol are contraindicated for use in premature infants. (see warnings and precautions, pediatric use .)